Pharma Update

Value Pipeline assets segmented by innovation potential Roche ranks #2 in number of NMEs with first-in-class potential Fast-follower Others* Total number of pipeline assets by innovation potential*, # First-in-class Peer 1 45 Roche 36 Peer 2 34 7 17 20 11 15 45 20 Peer 3 33 23 21 Peer 4 29 60 Peer 5 25 10 14 Peer 6 21 8 51 Peer 7 20 10 71 Peer 8 18 Peer 9 17 Peer 10 15 a Peer 11 15 1 LO Peer 12 12 28 19 32 35 43 *NMEs that are neither first-in-class or best-in-disease, or without disclosed MoA, are grouped as 'Others'; Peer 1-12 are other large-cap Pharma Source: Pharmaprojects (March 2023) Roche 25

View entire presentation